Mitoguazone therapy in patients with refractory or relapsed AIDS- related lymphoma: Results from a multicenter phase II trial

A. M. Levine, A. Tulpule, D. Tessman, L. Kaplan, F. Giles, B. D. Luskey, D. T. Scadden, Donald W Northfelt, I. Silverberg, J. Wernz, B. Espina, D. Von Hoff

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Purpose: Patients with AIDS-related lymphoma usually have extensive lymphomatous disease, with relatively frequent involvement of the CNS. Approximately half may achieve complete remission after chemotherapy. Mitoguazone, an inhibitor of polyamine biosynthesis, has demonstrated efficacy in patients with de nova recurrent lymphoma. The drug is relatively nonmyelotoxic and may cross the blood-brain barrier. The current study was designed to assess the safety and potential efficacy of mitoguazone in patients with relapsed or refractory AIDS-lymphoma. Patients and Methods: Thirty-five patients were accrued, all of whom had failed one (51%) or multiple (two to six) prior regimens. Mitoguazone (600 mg/m2) was given intravenously on days 1 and 8, and then every 2 weeks, until best response, progression, or toxicity. Results: The median age was 39 years. High-grade lymphoma was diagnosed in 29 patients (83%). Extranodal disease was present in 30 patients (86%), with multiple extranodal sites (two to seven) in 18 (51%). The median CD4 cell count at study entry was 66/dL (range, zero to 549). Twenty-six patients were assessable for response. The objective response rate was 23% (95% confidence interval [CI], 6.9 to 39.3), with complete remission in three patients (11.5%), and partial remission (PR) in three patients (11.5%). Six patients experienced stable disease. Median survival from study entry was 2.6 months for the group as a whole; 21.5 months (range, 3.8 to 29.1) in complete responders, 5.6 months (range, 3.8 to 34.8) in partial responders. The most common toxicities occurred solely during drug infusion and included vasodilation (63%), paresthesia (86%), and somnolence (17%). Fourteen patients (40%) experienced nausea and 16 (46%) vomiting (grade 3 in one). Ten patients (29%) developed stomatitis, including grade 3 in two and grade 4 in one. Seven patients (20%) developed neutropenia, with grade 4 in one. Thrombocytopenia occurred in nine patients (26%). While on study, three patients developed sepsis, four had pneumonia, and two developed opportunistic infections. Conclusion: Mitoguazone is an effective agent in patients with multiply relapsed or refractory AIDS- related lymphoma, with acceptable toxicity. Further study in patients with newly diagnosed disease is warranted.

Original languageEnglish (US)
Pages (from-to)1094-1103
Number of pages10
JournalJournal of Clinical Oncology
Volume15
Issue number3
StatePublished - Mar 1997
Externally publishedYes

Fingerprint

Mitoguazone
AIDS-Related Lymphoma
Therapeutics
Lymphoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Levine, A. M., Tulpule, A., Tessman, D., Kaplan, L., Giles, F., Luskey, B. D., ... Von Hoff, D. (1997). Mitoguazone therapy in patients with refractory or relapsed AIDS- related lymphoma: Results from a multicenter phase II trial. Journal of Clinical Oncology, 15(3), 1094-1103.

Mitoguazone therapy in patients with refractory or relapsed AIDS- related lymphoma : Results from a multicenter phase II trial. / Levine, A. M.; Tulpule, A.; Tessman, D.; Kaplan, L.; Giles, F.; Luskey, B. D.; Scadden, D. T.; Northfelt, Donald W; Silverberg, I.; Wernz, J.; Espina, B.; Von Hoff, D.

In: Journal of Clinical Oncology, Vol. 15, No. 3, 03.1997, p. 1094-1103.

Research output: Contribution to journalArticle

Levine, AM, Tulpule, A, Tessman, D, Kaplan, L, Giles, F, Luskey, BD, Scadden, DT, Northfelt, DW, Silverberg, I, Wernz, J, Espina, B & Von Hoff, D 1997, 'Mitoguazone therapy in patients with refractory or relapsed AIDS- related lymphoma: Results from a multicenter phase II trial', Journal of Clinical Oncology, vol. 15, no. 3, pp. 1094-1103.
Levine, A. M. ; Tulpule, A. ; Tessman, D. ; Kaplan, L. ; Giles, F. ; Luskey, B. D. ; Scadden, D. T. ; Northfelt, Donald W ; Silverberg, I. ; Wernz, J. ; Espina, B. ; Von Hoff, D. / Mitoguazone therapy in patients with refractory or relapsed AIDS- related lymphoma : Results from a multicenter phase II trial. In: Journal of Clinical Oncology. 1997 ; Vol. 15, No. 3. pp. 1094-1103.
@article{b6a1075693e54ef5b92391ef5eaf4bbb,
title = "Mitoguazone therapy in patients with refractory or relapsed AIDS- related lymphoma: Results from a multicenter phase II trial",
abstract = "Purpose: Patients with AIDS-related lymphoma usually have extensive lymphomatous disease, with relatively frequent involvement of the CNS. Approximately half may achieve complete remission after chemotherapy. Mitoguazone, an inhibitor of polyamine biosynthesis, has demonstrated efficacy in patients with de nova recurrent lymphoma. The drug is relatively nonmyelotoxic and may cross the blood-brain barrier. The current study was designed to assess the safety and potential efficacy of mitoguazone in patients with relapsed or refractory AIDS-lymphoma. Patients and Methods: Thirty-five patients were accrued, all of whom had failed one (51{\%}) or multiple (two to six) prior regimens. Mitoguazone (600 mg/m2) was given intravenously on days 1 and 8, and then every 2 weeks, until best response, progression, or toxicity. Results: The median age was 39 years. High-grade lymphoma was diagnosed in 29 patients (83{\%}). Extranodal disease was present in 30 patients (86{\%}), with multiple extranodal sites (two to seven) in 18 (51{\%}). The median CD4 cell count at study entry was 66/dL (range, zero to 549). Twenty-six patients were assessable for response. The objective response rate was 23{\%} (95{\%} confidence interval [CI], 6.9 to 39.3), with complete remission in three patients (11.5{\%}), and partial remission (PR) in three patients (11.5{\%}). Six patients experienced stable disease. Median survival from study entry was 2.6 months for the group as a whole; 21.5 months (range, 3.8 to 29.1) in complete responders, 5.6 months (range, 3.8 to 34.8) in partial responders. The most common toxicities occurred solely during drug infusion and included vasodilation (63{\%}), paresthesia (86{\%}), and somnolence (17{\%}). Fourteen patients (40{\%}) experienced nausea and 16 (46{\%}) vomiting (grade 3 in one). Ten patients (29{\%}) developed stomatitis, including grade 3 in two and grade 4 in one. Seven patients (20{\%}) developed neutropenia, with grade 4 in one. Thrombocytopenia occurred in nine patients (26{\%}). While on study, three patients developed sepsis, four had pneumonia, and two developed opportunistic infections. Conclusion: Mitoguazone is an effective agent in patients with multiply relapsed or refractory AIDS- related lymphoma, with acceptable toxicity. Further study in patients with newly diagnosed disease is warranted.",
author = "Levine, {A. M.} and A. Tulpule and D. Tessman and L. Kaplan and F. Giles and Luskey, {B. D.} and Scadden, {D. T.} and Northfelt, {Donald W} and I. Silverberg and J. Wernz and B. Espina and {Von Hoff}, D.",
year = "1997",
month = "3",
language = "English (US)",
volume = "15",
pages = "1094--1103",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "3",

}

TY - JOUR

T1 - Mitoguazone therapy in patients with refractory or relapsed AIDS- related lymphoma

T2 - Results from a multicenter phase II trial

AU - Levine, A. M.

AU - Tulpule, A.

AU - Tessman, D.

AU - Kaplan, L.

AU - Giles, F.

AU - Luskey, B. D.

AU - Scadden, D. T.

AU - Northfelt, Donald W

AU - Silverberg, I.

AU - Wernz, J.

AU - Espina, B.

AU - Von Hoff, D.

PY - 1997/3

Y1 - 1997/3

N2 - Purpose: Patients with AIDS-related lymphoma usually have extensive lymphomatous disease, with relatively frequent involvement of the CNS. Approximately half may achieve complete remission after chemotherapy. Mitoguazone, an inhibitor of polyamine biosynthesis, has demonstrated efficacy in patients with de nova recurrent lymphoma. The drug is relatively nonmyelotoxic and may cross the blood-brain barrier. The current study was designed to assess the safety and potential efficacy of mitoguazone in patients with relapsed or refractory AIDS-lymphoma. Patients and Methods: Thirty-five patients were accrued, all of whom had failed one (51%) or multiple (two to six) prior regimens. Mitoguazone (600 mg/m2) was given intravenously on days 1 and 8, and then every 2 weeks, until best response, progression, or toxicity. Results: The median age was 39 years. High-grade lymphoma was diagnosed in 29 patients (83%). Extranodal disease was present in 30 patients (86%), with multiple extranodal sites (two to seven) in 18 (51%). The median CD4 cell count at study entry was 66/dL (range, zero to 549). Twenty-six patients were assessable for response. The objective response rate was 23% (95% confidence interval [CI], 6.9 to 39.3), with complete remission in three patients (11.5%), and partial remission (PR) in three patients (11.5%). Six patients experienced stable disease. Median survival from study entry was 2.6 months for the group as a whole; 21.5 months (range, 3.8 to 29.1) in complete responders, 5.6 months (range, 3.8 to 34.8) in partial responders. The most common toxicities occurred solely during drug infusion and included vasodilation (63%), paresthesia (86%), and somnolence (17%). Fourteen patients (40%) experienced nausea and 16 (46%) vomiting (grade 3 in one). Ten patients (29%) developed stomatitis, including grade 3 in two and grade 4 in one. Seven patients (20%) developed neutropenia, with grade 4 in one. Thrombocytopenia occurred in nine patients (26%). While on study, three patients developed sepsis, four had pneumonia, and two developed opportunistic infections. Conclusion: Mitoguazone is an effective agent in patients with multiply relapsed or refractory AIDS- related lymphoma, with acceptable toxicity. Further study in patients with newly diagnosed disease is warranted.

AB - Purpose: Patients with AIDS-related lymphoma usually have extensive lymphomatous disease, with relatively frequent involvement of the CNS. Approximately half may achieve complete remission after chemotherapy. Mitoguazone, an inhibitor of polyamine biosynthesis, has demonstrated efficacy in patients with de nova recurrent lymphoma. The drug is relatively nonmyelotoxic and may cross the blood-brain barrier. The current study was designed to assess the safety and potential efficacy of mitoguazone in patients with relapsed or refractory AIDS-lymphoma. Patients and Methods: Thirty-five patients were accrued, all of whom had failed one (51%) or multiple (two to six) prior regimens. Mitoguazone (600 mg/m2) was given intravenously on days 1 and 8, and then every 2 weeks, until best response, progression, or toxicity. Results: The median age was 39 years. High-grade lymphoma was diagnosed in 29 patients (83%). Extranodal disease was present in 30 patients (86%), with multiple extranodal sites (two to seven) in 18 (51%). The median CD4 cell count at study entry was 66/dL (range, zero to 549). Twenty-six patients were assessable for response. The objective response rate was 23% (95% confidence interval [CI], 6.9 to 39.3), with complete remission in three patients (11.5%), and partial remission (PR) in three patients (11.5%). Six patients experienced stable disease. Median survival from study entry was 2.6 months for the group as a whole; 21.5 months (range, 3.8 to 29.1) in complete responders, 5.6 months (range, 3.8 to 34.8) in partial responders. The most common toxicities occurred solely during drug infusion and included vasodilation (63%), paresthesia (86%), and somnolence (17%). Fourteen patients (40%) experienced nausea and 16 (46%) vomiting (grade 3 in one). Ten patients (29%) developed stomatitis, including grade 3 in two and grade 4 in one. Seven patients (20%) developed neutropenia, with grade 4 in one. Thrombocytopenia occurred in nine patients (26%). While on study, three patients developed sepsis, four had pneumonia, and two developed opportunistic infections. Conclusion: Mitoguazone is an effective agent in patients with multiply relapsed or refractory AIDS- related lymphoma, with acceptable toxicity. Further study in patients with newly diagnosed disease is warranted.

UR - http://www.scopus.com/inward/record.url?scp=0031044608&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031044608&partnerID=8YFLogxK

M3 - Article

C2 - 9060550

AN - SCOPUS:0031044608

VL - 15

SP - 1094

EP - 1103

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 3

ER -